
Quarterly report 2025-Q3
added 11-14-2025
TELA Bio Net Debt 2011-2026 | TELA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt TELA Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.65 M | -1.76 M | -12.4 M | -43.6 M | -5.77 M | 12.5 M | -6.83 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 M | -43.6 M | -9.08 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
-4.85 M | $ 2.19 | 3.79 % | $ 3.42 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 10.66 | 2.3 % | $ 1.44 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.08 | 4.09 % | $ 864 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 12.79 | 1.51 % | $ 1.92 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.36 | -0.24 % | $ 600 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 71.81 | 2.94 % | $ 106 B | ||
|
CONMED Corporation
CNMD
|
802 M | $ 36.75 | -1.76 % | $ 1.14 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.69 | 6.83 % | $ 37.6 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.12 | 3.91 % | $ 154 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Establishment Labs Holdings
ESTA
|
174 M | $ 64.8 | 2.08 % | $ 1.92 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 11.12 | 0.82 % | $ 301 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.43 | 0.08 % | $ 121 M | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.22 | 1.37 % | $ 1.35 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 13.58 | 1.08 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.31 | -1.5 % | $ 21.1 M | ||
|
Abbott Laboratories
ABT
|
1.65 B | $ 111.67 | 1.56 % | $ 194 B | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.84 | 0.31 % | $ 352 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 268.33 | 2.72 % | $ 7.57 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.19 | 2.0 % | $ 708 M | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 62.26 | 1.34 % | $ 3.4 B | ||
|
AxoGen
AXGN
|
15.2 M | $ 32.83 | -0.03 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
-925 M | $ 176.49 | 4.15 % | $ 13.2 B | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 33.53 | 2.35 % | $ 5 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.77 | 2.72 % | $ 155 M | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 17.17 | 0.35 % | $ 403 M | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 86.71 | 3.14 % | $ 3.01 B | ||
|
MiMedx Group
MDXG
|
-148 M | $ 4.46 | 1.02 % | $ 659 M |